Maia Biotech wins Spanish, Portuguese regulatory clearance to screen patients in THIO-104 lung cancer trial - MAIA News | RalliesMaia Biotech wins Spanish, Portuguese regulatory clearance to screen patients in THIO-104 lung cancer trial
M
MAIA• Regulatory clearance expands THIO-104 trial in Europe
- Maia Biotechnology won regulatory clearance in Spain and Portugal to start screening for its Phase 3 THIO-104 NSCLC trial.
- AEMPS and INFARMED authorizations extend the pivotal study’s European footprint ahead of a planned 2027 interim survival analysis.
- The trial has enrolled 65 patients to date; the target is 100 dosed by year-end 2026.
RAIN
•
